A Phase 2, Adaptive, Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Intravenous AMB-05X in Subjects With Tenosynovial Giant Cell Tumor

AMB-05X

Treatment-emergent Adverse Events (TEAEs)

Overall Tumor Response (Objective Response) Per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1

Overall Response Based on Tumor Volume Score (TVS)

Mean Change From Baseline Range of Motion (ROM) (Flexion, Knee) Scores

Mean Change From Baseline in the Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function Score

Serum Cmax for AMB-05X at Week 10 Post Dose

Number of Subjects With Anti-Drug Antibodies to AMB-05X at Week 10

Mean Change From Baseline in Worst Stiffness Numeric Rating Scale (NRS) Score

Brief Pain Inventory Pain Severity Domain Score

Mean Change From Baseline in Brief Pain Inventory Severity Interference

Worst Pain Numeric Rating Scale Score

EuroQol 5 Dimension 5 Level Health Assessment

Colony-stimulating Factor 1 Levels

Mean Change From Baseline Rnge of Motion (Flexion, Ankle) Scores

Serum AMB-05X-Binding Anti-drug Antibody (ADA) Levels